Allergy Asthma Respir Dis.
2020 Apr;8(2):53-65. 10.4168/aard.2020.8.2.53.
Intralymphatic allergen-specific immunotherapy
- Affiliations
-
- 1Division of Pulmonology and Allergy, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon; 2Department of Otolaryngology-Head and Neck Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
- KMID: 2500179
- DOI: http://doi.org/10.4168/aard.2020.8.2.53
Abstract
- Although allergen-specific immunotherapy (AIT) is a standard treatment for allergic diseases, only 5% or less of patients in whom AIT is indicated have been receiving immunotherapy because AIT needs a long-term therapeutic duration of up to 5 years. To overcome this limitation of conventional AIT, Kündig and his colleagues first introduced intralymphatic immunotherapy (ILIT) in patients with allergic rhinitis, publishing their results in 2008. Since then, 10 clinical trials that evaluated therapeutic efficacies and adverse effects of ILIT have been conducted. This article reviews the clinical trials of ILIT and suggests unmet needs in research fields of ILIT.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Allergen-specific intralymphatic immunotherapy in human and animal studies
- Recent Advances in Allergen-Specific Immunotherapy in Humans: A Systematic Review
- Allergen Specific Immunotherapy in Allergic Rhinitis
- Allergen specific IgG antibodies in nasal secretion during allergen specific immunotherapy
- Two Cases of Atopic Dermatitis Improved by Combination Treatment of Allergen-Specific Immunotherapy and Histamine-Immunoglobulin Complex
